Spotlight—author’s view for “Metabolic glycan labeling immobilizes dendritic cell membrane and enhances antitumorefficacy of dendritic cell vaccine”
Spotlight—author’s view for “Metabolic glycan labeling immobilizes dendritic cell membrane and enhances antitumorefficacy of dendritic cell vaccine”
复制标题
Spotlight——作者对“代谢聚糖标记固定树突状细胞膜并增强树突状细胞疫苗的抗肿瘤功效”的观点
DOI：
10.1038/s41435-023-00245-4
复制
发表时间：
2023
期刊：
影响因子：
5
通讯作者：
Wang, Hua
中科院分区：
文献类型：
--
作者：
Zhou, Jiadiao;Wang, Hua
树突状细胞（DC）疫苗是FDA批准的第一种癌症免疫疗法之一，但受到适度的细胞毒性T淋巴细胞（CTL）应答和治疗效果的限制。在这里，我们报告了一种简便的代谢标记方法，使过继转移的DC开发增强的DC疫苗的靶向调制。我们发现，代谢性聚糖标记可以降低DC的膜迁移率，从而激活DC并改善DC的抗原呈递和随后的T细胞引发性质。代谢聚糖标记本身可以增强DC疫苗的抗肿瘤功效。此外，细胞表面化学标签（例如，通过代谢聚糖标记引入的细胞因子（例如，叠氮基）也能够使细胞因子在体内缀合到过继转移的DC上，这进一步增强了CTL应答和抗肿瘤功效。我们的DC标记和靶向技术提供了一种提高DC疫苗治疗效果的策略，对临床生产过程的干扰最小。
Dendritic cell (DC) vaccine was among the first FDA-approved cancer immunotherapies, but has been limited by the modest cytotoxic T lymphocyte (CTL) response and therapeutic efficacy. Here we report a facile metabolic labeling approach that enables targeted modulation of adoptively transferred DCs for developing enhanced DC vaccines. We show that metabolic glycan labeling can reduce the membrane mobility of DCs, which activates DCs and improves the antigen presentation and subsequent T cell priming property of DCs. Metabolic glycan labeling itself can enhance the antitumor efficacy of DC vaccines. In addition, the cell-surface chemical tags (e.g., azido groups) introduced via metabolic glycan labeling also enable in vivo conjugation of cytokines onto adoptively transferred DCs, which further enhances CTL response and antitumor efficacy. Our DC labeling and targeting technology provides a strategy to improve the therapeutic efficacy of DC vaccines, with minimal interference upon the clinical manufacturing process.
影响因子：
16.6
作者：
Han, Joonsu;Bhatta, Rimsha;Liu, Yusheng;Bo, Yang;Elosegui-Artola, Alberto;Wang, Hua
通讯作者：
Wang, Hua